

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

FHL/SEC/2025-26

July 20, 2025

The National Stock Exchange of India Ltd.
Scrip Symbol: FORTIS

BSE Limited
Scrip Code:532843

Sub.: Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations).

Dear Sir/ Ma'am,

In terms of Regulation 30(4) of SEBI Listing Regulations read with SEBI Master Circular dated November 11, 2024, we hereby submit the details of order dated July 17, 2025 passed by the Hon'ble High Court of Delhi, as made available earlier today, as per details given in the Annexure A.

The Hon'ble Delhi High Court had ordered for the sale of the 'SRL Trademarks' ("SRL Marks") by way of public auction, as, pursuant to the Hon'ble Supreme Court of India's judgment dated September 22, 2022, the SRL Marks (which were held by certain entities owned and controlled by the erstwhile promoters of the Company) were attached and made available to the Hon'ble Delhi High Court for satisfaction of a decree in favour of Daiichi Sankyo Company Limited ("Daiichi"). A public auction was conducted, wherein Agilus Diagnostics Limited (a subsidiary of the Company) ("Agilus") emerged as the successful bidder for the SRL Marks basis its bid of INR 8 crores. Agilus duly deposited the entire bid amount in the Hon'ble Delhi High Court. Subsequently, Daiichi filed an application seeking confirmation of sale and withdrawal of the amount deposited by Agilus. By way of its order dated July 17, 2025, the Hon'ble Delhi High Court has allowed the aforesaid application filed by Daiichi. Further details are set out in Annexure A below.

The date and time of occurrence of event was July 20, 2025 at 6:36 p.m.

This is for your information and record.

Thanking you,
Yours sincerely,
For **Fortis Healthcare Limited**

Satyendra Chauhan
Company Secretary & Compliance Officer
M. No. – A14783

Encl: a/a

FORTIS HEALTHCARE LIMITED

Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062
Tel : 0172-5096001, Fax : 0172-5096221, CIN : L85110PB1996PLC045933

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

Annexure-A

<p>Brief details of the litigation viz. name(s) of the opposing party, court/tribunal/agency where litigation is filed, brief details of dispute/litigation</p>	<p><i>Brief background:</i></p> <p>An arbitral award dated April 29, 2016 was passed by a Singapore arbitral tribunal in favour of Daiichi Sankyo Company Limited (“Daiichi”) and against 20 respondents (including against a company called RHC Holding Private Limited (“RHC Holding”). The arbitral award has attained finality and is now a decree in favour of Daiichi (“Decree”), that is being executed by the Hon’ble High Court of Delhi (“Delhi High Court”).</p> <p>RHC Holding was the legal and beneficial owner of the ‘SRL’ trademarks (“SRL Marks”) and had granted Agilus Diagnostics Limited and Agilus Pathlabs Private Limited (subsidiaries of the Company) a non-exclusive license to use the SRL Marks under a brand licensing arrangement. At some point in 2017, RHC Holding assigned and transferred all rights in the Fortis Marks to Headway Brands Private Limited (“Headway”).</p> <p>Thereafter, <i>vide</i> judgment dated September 22, 2022, the Hon’ble Supreme Court of India held that all the properties of Malvinder Mohan Singh and Shivinder Mohan Singh (the erstwhile promoters of the Company), shall be available to the Delhi High Court in its capacity as the executing court, and that all such properties (including the SRL Marks) stand attached and are available for the Delhi High Court to pass such directions as it may deem appropriate to pass.</p> <p><i>Public Auction of SRL Marks:</i></p> <p>In connection with the satisfaction of the Decree, and pursuant to the aforesaid attachment of the SRL Marks, Daiichi had filed before the Delhi High Court certain applications praying for the appointment of a Court Commissioner for the purposes of carrying out the sale of the SRL Marks. <i>Vide</i> order dated December 04, 2023, the Court Commissioner was appointed to carry out the sale of the SRL Marks by public auction and the sale proclamation was approved <i>vide</i> order dated December 15, 2023. However, despite publication of the proclamation, no buyers turned up for the auction of the SRL Marks and no bids were received.</p> <p>Subsequently, in respect of a fresh application filed by Daiichi, the Delhi High Court had again ordered for the sale of the SRL</p>
---	---

FORTIS HEALTHCARE LIMITED

Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062

Tel : 0172-5096001, Fax : 0172-5096221, CIN : L85110PB1996PLC045933



Fortis Healthcare Limited

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

	<p>Marks by way of public auction and appointed a Joint Registrar (Judicial) of the Delhi High Court (“Joint Registrar”) for this purpose. In furtherance of the same, a public auction was carried out as per the procedures and conditions of sale stipulated by the Hon’ble Delhi High Court.</p> <p>Agilus Diagnostics Limited (a subsidiary of the Company) (“Agilus”) emerged as the successful bidder basis its bid of INR 8 crores for the SRL Marks, pursuant to which Agilus duly deposited the entire bid amount. Subsequently, Daiichi filed an application seeking confirmation of sale and withdrawal of the amount deposited by Agilus.</p> <p>The Hon’ble Delhi High Court has, by way of order dated July 17, 2025, allowed the aforesaid application filed by Daiichi.</p>
Expected financial implications, if any, due to compensation, penalty etc.	Not applicable. No financial implications due to compensation or penalty shall arise to the account of the Company on account of the sale of the SRL Marks.
Quantum of claims, if any.	Not Applicable.
The details of any change in the status and/or any development in relation to such proceedings.	As mentioned above.
In the case of litigation against key management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and/or any development in relation to such proceedings.	Not Applicable.
In the event of settlement of the proceedings, details of such settlement including – terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.	Not Applicable.

FORTIS HEALTHCARE LIMITED

Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062

Tel : 0172-5096001, Fax : 0172-5096221, CIN : L85110PB1996PLC045933